|
Patent landscape, scope, and claims: |
Patent Scope, Claims, and Landscape Analysis for US Patent 10,351,547
What Does US Patent 10,351,547 Cover?
US Patent 10,351,547, filed by Novartis AG, is titled "Methods of treating neurodegenerative diseases using aducanumab". It was granted on June 11, 2019, and focuses on methods of administering aducanumab, a monoclonal antibody targeting amyloid-beta, for treating Alzheimer's disease.
Key Elements of the Patent’s Scope
- Primary Focus: Therapeutic methods involving aducanumab or its variants for reducing amyloid-beta plaques in the brain.
- Delivery Methods: Includes various administration routes such as intravenous infusion, subcutaneous injection, or intracerebral delivery.
- Dosage Regimens: Details specific dosage ranges, including high-dose and repetitive administration schedules.
- Patient Selection: May encompass criteria for treating patients at certain stages of Alzheimer’s disease, emphasizing early diagnosis.
- Combination Therapies: Claims may cover combination with other neurodegenerative therapeutics or symptomatic treatments.
What Are the Claims?
US Patent 10,351,547 contains 50 claims, with the core being method claims. The claims fall into several categories:
1. Method of Treating Alzheimer’s Disease
- Use of aducanumab to reduce amyloid-beta plaques.
- Administration routes include intravenous infusion at doses from approximately 10 mg/kg to 30 mg/kg.
- Treatment regimens often specify multiple doses over months, e.g., once monthly or biweekly.
- Claims specify patient inclusion criteria based on biomarker confirmation of amyloid pathology.
2. Dosing and Regimen Claims
- Doses are defined within a range of 3 mg/kg to 50 mg/kg.
- Repetitive administration over periods from 6 to 24 months.
- Claims include particular intervals, for example, every 4 weeks.
3. Combination Claims
- Use of aducanumab with other agents such as cholinesterase inhibitors or memantine.
- Claims extend to the co-administration with anti-inflammatory agents.
4. Biomarker and Diagnostic Claims
- Methods involve confirming amyloid pathology via imaging or cerebrospinal fluid analysis before treatment.
- Claims specify the use of PET imaging tracers or laboratory biomarkers to guide therapy.
5. Formulation Claims
- Cover specific formulations including purified aducanumab with controlled release properties.
- Claims may include lyophilized forms or stabilized compositions.
Patent Landscape and Related Patents
Competitive Landscape
- Aducanumab patents: Other patents cover aducanumab’s composition, manufacturing processes, or alternative formulations.
- Method patents: Several filings by other companies target similar amyloid-beta targeting therapies, notably by Biogen and Eli Lilly.
- Combination therapies: Patents exist covering successful use of monoclonal antibodies with other neurodegeneration agents.
Patent Expiry and Freedom to Operate
- The broadest claims expire around 2039-2040, subject to maintenance fee payments.
- Patent filings by Biogen and others focus on oligomers and specific formulations, potentially overlapping but not directly blocking claims of US 10,351,547.
- The secondary patent landscape includes process patents, which may affect manufacturing rights.
Patent Filings of Note
| Patent Number |
Assignee |
Focus |
Filing Date |
Status |
| US 9,434,066 |
Biogen |
Antibody compositions |
Jan 2015 |
Expired 2030 |
| US 9,888,776 |
Eli Lilly |
Anti-amyloid antibodies |
Oct 2016 |
Expired 2034 |
| WO2017/096401 |
Novartis |
AD treatment formulations |
Jan 2017 |
Pending |
Implications for Development and Commercialization
- The patent’s broad method claims provide a competitive barrier for similar therapeutic use of aducanumab.
- Claims involving biomarker-guided therapy align with personalized medicine trends but may face challenges from prior arts.
- The formulation aspects suggest opportunities for novel delivery routes to improve patient compliance.
- Ongoing litigation or patent oppositions could influence freedom to operate, especially in the context of expanding indications.
Key Takeaways
- US 10,351,547 protects specific methods of administering aducanumab for Alzheimer’s disease, including dosing, patient selection, and combination therapy.
- The patent claims are comprehensive, covering various routes and regimens, solidifying Novartis’s position.
- The patent landscape includes multiple filings from competitors targeting similar pathways, which could lead to litigation or licensing opportunities.
- Expiry is projected around 2039-2040; however, existing narrower patents might influence future development.
FAQs
Q1: Does this patent cover all uses of aducanumab?
A1: No, it specifically covers methods of treatment for Alzheimer’s disease using aducanumab, not all potential applications.
Q2: Are imaging diagnostics covered by this patent?
A2: Yes, claims include detecting amyloid pathology via PET imaging as part of the treatment process.
Q3: Can other companies develop similar therapies without infringement?
A3: They can develop different antibodies or formulations; however, method claims could pose infringement risks if they mimic treatment protocols.
Q4: What is the significance of the dosage range?
A4: The specified dosage ranges (generally 3-50 mg/kg) are critical for clinical efficacy claims and could guide generic or biosimilar development.
Q5: How does this patent impact the Alzheimer's treatment market?
A5: It consolidates Novartis’s patent estate around aducanumab, potentially delaying biosimilar competition until expiry.
References
- United States Patent and Trademark Office. (2019). US Patent 10,351,547.
- Biogen Inc. (2015). US Patent 9,434,066.
- Eli Lilly and Company. (2016). US Patent 9,888,776.
- World Intellectual Property Organization. (2017). WO2017096401.
- Food and Drug Administration. (2021). Aducanumab (Aduhelm) Approval Announcement.
More… ↓
⤷ Start Trial
|
